Cargando…
Levels of Soluble Receptor for Advanced Glycation End Products in Bronchoalveolar Lavage Fluid in Patients with Various Inflammatory Lung Diseases
Receptor for advanced glycation end products (RAGE) is a multiligand receptor of S100/calgranulins, high-mobility group box 1, and others, and it is associated with the pathogenesis of various inflammatory and circulatory diseases. The soluble form of RAGE (sRAGE) is a decoy receptor and competitive...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4852761/ https://www.ncbi.nlm.nih.gov/pubmed/27147899 http://dx.doi.org/10.4137/CCRPM.S23326 |
_version_ | 1782429986756493312 |
---|---|
author | Kamo, Tetsuro Tasaka, Sadatomo Tokuda, Yuriko Suzuki, Shoji Asakura, Takanori Yagi, Kazuma Namkoong, Ho Ishii, Makoto Hasegawa, Naoki Betsuyaku, Tomoko |
author_facet | Kamo, Tetsuro Tasaka, Sadatomo Tokuda, Yuriko Suzuki, Shoji Asakura, Takanori Yagi, Kazuma Namkoong, Ho Ishii, Makoto Hasegawa, Naoki Betsuyaku, Tomoko |
author_sort | Kamo, Tetsuro |
collection | PubMed |
description | Receptor for advanced glycation end products (RAGE) is a multiligand receptor of S100/calgranulins, high-mobility group box 1, and others, and it is associated with the pathogenesis of various inflammatory and circulatory diseases. The soluble form of RAGE (sRAGE) is a decoy receptor and competitively inhibits membrane-bound RAGE activation. In this study, we measured sRAGE levels in bronchoalveolar lavage fluid (BALF) of 78 patients, including 41 with interstitial pneumonia, 11 with sarcoidosis, 9 with respiratory infection, 7 with ARDS, 5 with lung cancer, and 5 with vasculitis. Among them, sRAGE was detectable in BALF of 73 patients (94%). In patients with ARDS and vasculitis, the sRAGE levels were significantly higher than in the control subjects and those with interstitial pneumonia. The sRAGE levels were positively correlated with total cell counts in BALF and serum levels of surfactant protein-D, lactate dehydrogenase, and C-reactive protein. There was an inverse correlation between PaO(2)/FIO(2) ratio and sRAGE levels. These results indicate that sRAGE in BALF might be considered as a biomarker of lung inflammatory disorders, especially ARDS and vasculitis. |
format | Online Article Text |
id | pubmed-4852761 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Libertas Academica |
record_format | MEDLINE/PubMed |
spelling | pubmed-48527612016-05-04 Levels of Soluble Receptor for Advanced Glycation End Products in Bronchoalveolar Lavage Fluid in Patients with Various Inflammatory Lung Diseases Kamo, Tetsuro Tasaka, Sadatomo Tokuda, Yuriko Suzuki, Shoji Asakura, Takanori Yagi, Kazuma Namkoong, Ho Ishii, Makoto Hasegawa, Naoki Betsuyaku, Tomoko Clin Med Insights Circ Respir Pulm Med Original Research Receptor for advanced glycation end products (RAGE) is a multiligand receptor of S100/calgranulins, high-mobility group box 1, and others, and it is associated with the pathogenesis of various inflammatory and circulatory diseases. The soluble form of RAGE (sRAGE) is a decoy receptor and competitively inhibits membrane-bound RAGE activation. In this study, we measured sRAGE levels in bronchoalveolar lavage fluid (BALF) of 78 patients, including 41 with interstitial pneumonia, 11 with sarcoidosis, 9 with respiratory infection, 7 with ARDS, 5 with lung cancer, and 5 with vasculitis. Among them, sRAGE was detectable in BALF of 73 patients (94%). In patients with ARDS and vasculitis, the sRAGE levels were significantly higher than in the control subjects and those with interstitial pneumonia. The sRAGE levels were positively correlated with total cell counts in BALF and serum levels of surfactant protein-D, lactate dehydrogenase, and C-reactive protein. There was an inverse correlation between PaO(2)/FIO(2) ratio and sRAGE levels. These results indicate that sRAGE in BALF might be considered as a biomarker of lung inflammatory disorders, especially ARDS and vasculitis. Libertas Academica 2016-04-28 /pmc/articles/PMC4852761/ /pubmed/27147899 http://dx.doi.org/10.4137/CCRPM.S23326 Text en © 2015 the author(s), publisher and licensee Libertas Academica Ltd. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License. |
spellingShingle | Original Research Kamo, Tetsuro Tasaka, Sadatomo Tokuda, Yuriko Suzuki, Shoji Asakura, Takanori Yagi, Kazuma Namkoong, Ho Ishii, Makoto Hasegawa, Naoki Betsuyaku, Tomoko Levels of Soluble Receptor for Advanced Glycation End Products in Bronchoalveolar Lavage Fluid in Patients with Various Inflammatory Lung Diseases |
title | Levels of Soluble Receptor for Advanced Glycation End Products in Bronchoalveolar Lavage Fluid in Patients with Various Inflammatory Lung Diseases |
title_full | Levels of Soluble Receptor for Advanced Glycation End Products in Bronchoalveolar Lavage Fluid in Patients with Various Inflammatory Lung Diseases |
title_fullStr | Levels of Soluble Receptor for Advanced Glycation End Products in Bronchoalveolar Lavage Fluid in Patients with Various Inflammatory Lung Diseases |
title_full_unstemmed | Levels of Soluble Receptor for Advanced Glycation End Products in Bronchoalveolar Lavage Fluid in Patients with Various Inflammatory Lung Diseases |
title_short | Levels of Soluble Receptor for Advanced Glycation End Products in Bronchoalveolar Lavage Fluid in Patients with Various Inflammatory Lung Diseases |
title_sort | levels of soluble receptor for advanced glycation end products in bronchoalveolar lavage fluid in patients with various inflammatory lung diseases |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4852761/ https://www.ncbi.nlm.nih.gov/pubmed/27147899 http://dx.doi.org/10.4137/CCRPM.S23326 |
work_keys_str_mv | AT kamotetsuro levelsofsolublereceptorforadvancedglycationendproductsinbronchoalveolarlavagefluidinpatientswithvariousinflammatorylungdiseases AT tasakasadatomo levelsofsolublereceptorforadvancedglycationendproductsinbronchoalveolarlavagefluidinpatientswithvariousinflammatorylungdiseases AT tokudayuriko levelsofsolublereceptorforadvancedglycationendproductsinbronchoalveolarlavagefluidinpatientswithvariousinflammatorylungdiseases AT suzukishoji levelsofsolublereceptorforadvancedglycationendproductsinbronchoalveolarlavagefluidinpatientswithvariousinflammatorylungdiseases AT asakuratakanori levelsofsolublereceptorforadvancedglycationendproductsinbronchoalveolarlavagefluidinpatientswithvariousinflammatorylungdiseases AT yagikazuma levelsofsolublereceptorforadvancedglycationendproductsinbronchoalveolarlavagefluidinpatientswithvariousinflammatorylungdiseases AT namkoongho levelsofsolublereceptorforadvancedglycationendproductsinbronchoalveolarlavagefluidinpatientswithvariousinflammatorylungdiseases AT ishiimakoto levelsofsolublereceptorforadvancedglycationendproductsinbronchoalveolarlavagefluidinpatientswithvariousinflammatorylungdiseases AT hasegawanaoki levelsofsolublereceptorforadvancedglycationendproductsinbronchoalveolarlavagefluidinpatientswithvariousinflammatorylungdiseases AT betsuyakutomoko levelsofsolublereceptorforadvancedglycationendproductsinbronchoalveolarlavagefluidinpatientswithvariousinflammatorylungdiseases |